General description
A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma cells, which can be blocked by Caspase Inhibitor Z-VAD-FMK (Cat. No. 627610).
A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
HDAC
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Coffey, D.C., et al. 2001. Cancer Res.61, 3591.
Coffey, D.C., et al. 2000. Pediatr. Oncol.35, 577.
Marks, P.A., et al. 2000. J. Natl. Cancer Inst.92, 1210.
Glick, R.D., et al. 1999. Cancer Res.59, 4392.
Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA95, 3003.
Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA93, 5705.
Legal Information
Not available for sale in the United States.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51303603
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 382148-5MG